First Manhattan’s Taysha Gene Therapies TSHA Stock Holding History

First Manhattan’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296K	Hold	43,500	–	–	﹤0.01%	661
2026 Q1	$194K	Hold	43,500	–	–	﹤0.01%	728
2025 Q4	$239K	Buy	43,500 +15,000	+53%	+$72.8K	﹤0.01%	677
2025 Q3	$93.2K	Hold	28,500	–	–	﹤0.01%	702
2025 Q2	$65.8K	Hold	28,500	–	–	﹤0.01%	692
2025 Q1	$39.6K	Hold	28,500	–	–	﹤0.01%	672
2024 Q4	$49.3K	Buy	+28,500	New	+$59.1K	﹤0.01%	673

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan's TSHA Position: Q2 2026 in Review

First Manhattan held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 43,500 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

First Manhattan first reported a position in TSHA in Q4 2024 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

First Manhattan held 43,500 shares of Taysha Gene Therapies worth $296K as of Q2 2026.
First Manhattan left its Taysha Gene Therapies share count unchanged in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of First Manhattan's portfolio in Q2 2026, its #661 holding.
First Manhattan first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 7 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.